Professor | Page 324 of 349

Health :: Predicting PET Imaging’s Future: Diagnosing and Treating Diseases ASAP

Breakthroughs in Sensitivity and Resolution Benefit Patients, Fundamentally Change How Doctors Will Diagnose and Treat Cancer and Heart, Brain Diseases, Notes Article in November Journal of Nuclear Medicine – Imagine a new world of detecting and diagnosing diseases sooner?even before any symptoms are present. Consider the possibility of receiving individualized, targeted molecular, cellular or genetic medical treatment as soon as possible and of undergoing scanning that can quickly tell your doctor whether your treatment is working. Continued advances in positron emission tomography (PET) imaging are key to this future, according to Simon R. Cherry, professor of biomedical engineering at the University of California, Davis.

Breast Cancer :: Unique estrogen receptor linked to metastatic breast cancer

Providence, RI ?V Breast cancer awareness month may have passed, but researchers remain focused on the disease with a new study showing that a unique estrogen receptor found in breast cancer tumors is a predictor of tumor size and metastases. The study, led by researchers at Rhode Island Hospital and Brown Medical School, is published in the November 1 issue of Clinical Cancer Research.

Multiple Sclerosis :: Explaining the risk and benefits of treatment options

In August 2004, the Royal College of Physicians (RCP) began work on a programme called ‘Communication between patients and their hospital doctor’ in order to suggest ways in which greater understanding of the doctor/patient partnership can produce more effective treatment and care.

Baby Care :: Neonatal Intensive Care Unit Program Reduces Premature Infants’ Length of Stay

An educational intervention program for parents of infants born prematurely that is implemented early in the Neonatal Intensive Care Unit (NICU) can reduce parental stress, depression and anxiety, enhance parent-infant interactions, and reduce hospital length of stay, according to a study led by Dr. Bernadette Melnyk, Dean and Distinguished Foundation Professor in Nursing at Arizona State University College of Nursing & Healthcare Innovation, Phoenix.

Kidney Stone :: Drug prescribed for migraines and seizures increases risk of kidney stones

Topiramate (Topamax), a drug commonly prescribed to treat seizures and migraine headaches, can increase the propensity of calcium phosphate kidney stones, researchers at UT Southwestern Medical Center have found.

Depression :: Carefully monitored treatment can help two-thirds of those who suffer from depression

More than two-thirds of people who suffer from major depression can become symptom-free if they are willing to work with their doctors and try various treatments to determine which work best for them, which may involve taking different antidepressants or adding cognitive therapy to the mix.

Stroke :: Two-Week Regimen Helps Stroke Survivors Regain Arm Control

In the largest, most comprehensive study of its kind to date, researchers supported by the National Institutes of Health (NIH) showed clinical improvements out to one year when stroke survivors who had lost function in one arm were given a unique, two-week rehabilitation regimen.

Macular Degeneration :: Laser Treatment Does Not Prevent Vision Loss for People with Early Age-Related Macular Degeneration

An extensive NIH-supported study has found that low-intensity laser treatment, thought to be possibly beneficial in slowing or preventing the loss of vision from age-related macular degeneration (AMD), is ineffective in preventing complications of AMD or loss of vision. This is the major conclusion of the Complications of Age-Related Macular Degeneration Prevention Trial (CAPT), a research study of more than 1,000 people that will be published in the November 2006 issue of the journal Ophthalmology. The study was supported by grants from the National Eye Institute (NEI) of the National Institutes of Health (NIH).

Restless Legs Syndrome :: Boehringer Ingelheim’s pramipexole effective in RLS patients

New data presented today show patients taking pramipexole (Mirapexin?/ Sifrol?) can experience significant improvements in a broad range of symptoms associated with Restless Legs Syndrome (RLS).1 In an additional study presented today, pramipexole was also shown to be well tolerated in RLS patients affected by concomitant diseases, which are commonly experienced in this patient group.2 The results of the studies were presented at the 10th International Congress of Parkinson?s Disease and Movement Disorders (MDS) in Kyoto, Japan.

Parkinson’s Disease :: Boehringer Ingelheim’s pramipexole, mirapexin/sifrol to improve depressive and motivational symptoms

New data presented today from a meta-analysis* of nearly 1,300 Parkinson?s disease (PD) patients, indicate that pramipexole (Mirapexin?/Sifrol?) has a beneficial effect on depressive and motivational symptoms in PD.1 This confirms findings from previously published clinical trials,2,3,4 and is in addition to its established efficacy in controlling motor symptoms. These findings are of particular interest as mood symptoms in PD can affect up to 50 percent of the patient population.1,5 The data were presented at the 10th International Congress of Parkinson?s Disease and Movement Disorders (MDS) in Kyoto, Japan.